Physician

Kerwin K Cumberbatch, M.D

According to 2025 Medicare claims, Kerwin Cumberbatch, M.D (NPI: 1669785788) practices medical oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Flagler, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32164-5979.

Cumberbatch's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 582 traditional Medicare patients, billed 38,020 HCPCS/CPT codes, and received $497,935 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 743 prescription claims across 145 beneficiaries totaling $1,542,745 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 29 claims. Open Payments data shows 1 records totaling $14. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $28,392 and ending at $497,935. Concurrently, Part D prescription costs have risen steadily, from $67,716 to $1,542,745. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $1,638 to $2,511.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	110	242	$28,392
2018	381	1,114	$137,107
2019	562	1,644	$173,332
2020	621	127,952	$1,278,350
2021	809	393,447	$4,380,134
2022	676	371,025	$4,577,065
2023	209	373	$36,634
2024	582	38,020	$497,935

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	16	57	$67,716
2016	34	127	$308,491
2017	46	157	$211,799
2018	63	307	$638,014
2019	115	577	$1,701,741
2020	171	1,050	$3,257,591
2021	200	1,385	$3,682,227
2022	187	1,387	$4,567,585
2023	107	391	$428,746
2024	145	743	$1,542,745

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	33	$634
2019	N/R	183	$14,113
2020	25	298	$18,561
2021	42	395	$19,228
2022	26	219	$9,858
2023	N/R	29	$2,488
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	126	204	$104
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	86	86	$80
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	152	207	$68
36415	Insertion of needle into vein for collection of blood sample	188	262	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	170	225	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	994	$605,359
Eliquis	Apixaban	67	2,265	$43,607
Abiraterone Acetate	Abiraterone Acetate	25	750	$30,454
Xarelto	Rivaroxaban	11	510	$9,371
Valacyclovir	Valacyclovir Hcl	46	1,560	$1,499

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$14	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kerwin K. Cumberbatch, M.D?

Tedicare shows public-source Medicare data for Kerwin K. Cumberbatch, M.D (NPI 1669785788), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kerwin K. Cumberbatch, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kerwin K. Cumberbatch, M.D?

Kerwin K. Cumberbatch, M.D is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Kerwin K. Cumberbatch, M.D have Open Payments data?

Kerwin K. Cumberbatch, M.D has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.